Trials / Completed
CompletedNCT01347983
Extension Study of Tocilizumab Long Term Treatment of Moderate to Severe Rheumatoid Arthritis Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 72 (actual)
- Sponsor
- Chugai Pharma Taiwan · Industry
- Sex
- All
- Age
- 20 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
24 week open-labeled extension study to continue monitoring the same group of patients in the previous MRA230TW phase IIIb trial in order to evaluate the long term efficacy and safety of tocilizumab.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tocilizumab+Methotrexate(MTX) | Tocilizumab: 8 mg/kg every 4 weeks, IV infusion Methotrexate: 10-20 mg/week |
Timeline
- Start date
- 2011-05-01
- Primary completion
- 2013-03-01
- Completion
- 2013-04-01
- First posted
- 2011-05-05
- Last updated
- 2013-04-04
Locations
12 sites across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT01347983. Inclusion in this directory is not an endorsement.